Yu Ding

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology · 2018 · 608 citations

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

Shifu Xiao, Piu Chan, Tao Wang et al. · Alzheimer s Research & Therapy · 2021 · 188 citations · Full text

Anti‐tumor and anti‐carcinogenic activities of triterpenoid, β‐boswellic acid

Mou‐Tuan Huang, Vladimir Badmaev, Yu Ding et al. · BioFactors · 2000 · 135 citations · Full text

Inflammation, Gum Resin Exudate, Boswellia Serrata +11

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

Peter Schmid, Javier Cortés, Rebecca Dent et al. · Annals of Oncology · 2021 · 130 citations · Full text

Medicine, Adjuvant Pembrolizumab, Immunology +9

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Fátima Cardoso, Heather L. McArthur, Peter Schmid et al. · Annals of Oncology · 2023 · 128 citations · Full text

Breast Oncology, Oncology, Lba21 Keynote-756 +9